chrisvoncsefalvay/vaers-outcomes huggingface dataset:
My vision went dark and I could not see the desk in front of me; My head went backward and hit thewall behind me.; I was shaking uncontrollably, I continued to shake uncontrollable for a total of about 30 minutes; continued to feel very weak and shake.; I continued to feel very weak; I was not doing well; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received an BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Pfizer ER8739) via an unspecified route of administration on 24Apr2021 at 09:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19.The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24Apr2021 at 09:15, while patient was siting in chair waiting the 15 minutes, the patient experienced that the vision went dark and could not see the desk in front of her, the head went backward and hit the wall behind her and was shaking uncontrollably. The patient continued to shake uncontrollably for a total of about 30 minutes and felt very scared. The patient had some water but was not doing well and after patient left facility, continued to feel very weak and shake. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events- the vision went dark and she could not see the desk in front of her, the head went backward and hit the wall behind her and was shaking uncontrollably, continued to shake uncontrollably, was not doing well and continued to feel very weak and shake was recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Arm has lump; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MASS (Arm has lump) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE MASS (Arm has lump). At the time of the report, VACCINATION SITE MASS (Arm has lump) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient reported that the event was still present after 4 weeks of vaccination. No relevant concomitant medications were reported. No treatment information was reported.   Most recent FOLLOW-UP information incorporated above includes: On 01-Jul-2021: Follow up received is non significant and only the contact information is updated. The event LLT/PT/ changed to Vaccination site mass as per MSA Comment. On 02-Aug-2021: Possible NNI.; Sender's Comments: Very limited information regarding the event have been provided at this time. No further information is expected.
The patient had mild vaginal spotting the day after her first Pfizer Covid shot (4-15-21) which lasted 1 day.  She gave it no mind.  But upon getting her second shot, she had several days of light spotting and reported to my office on 5-11-21 for an exam.  Bacterial vaginitis was diagnosed at that visit.  The patient wants this event reported, in case this is a legitimately linked event.
Sore throat Runny and stuffy nose Fever of 101.3 for 48 hrs Chills Muscle aches Fatigue Cough Headache Sneezing Fast heart rate
Breakthrough case admission after 4 vaccines Moderna 2/4/21 Lot# 013M20A;  Moderna 3/4/21 Lot# 030A21A;  Moderna 11/23/21 Lot# 012H21B;  Moderna 7/27/22 Lot# 006M21A
Intense shoulder pain at time of injection.  Shoulder joint pain, not actually at injection site.  24 hrs after shot got a high fever, vomiting, fainting, and still more shoulder pain.  Can not move my arm to brush teeth, brush hair, very limited mobility in the right arm.  Not getting better and this is day 4.
Injection site pain; Pain all over body; Muscle pain; Slight chills; Not really feeling well; Joint pain; Last night her couldn't sleep; This is a spontaneous report from a contactable consumer. A 69-years-old male patient received first dose of BNT162B2(PFIZER-BIONTECH COVID-19 VACCINE; Lot Number: EN6202), via an unspecified route of administration, administered in Arm Left on 04Mar2021 07:40 (at the age 69 years) as SINGLE for covid-19 immunization. Medical history included ongoing high blood pressure. Concomitant medications included olmesartan medoxomil taken for high blood pressure who has been on for more than a year and unspecified vitamins for general health. It was reported that during the day when he had the injection in Mar2021, he got the regular injection site pain and discomfort and that went away after day two. Since yesterday, he started having pain all over his body. He adds that it was really intense last night. He adds he also had muscle pain, slight chills, joint pain, not really feeling well. He goes for quick walks sometimes and he does have reaction to some stuff. He adds that for some of those things he has a pen. He has joint pain if he eats wheat.  He normally has some pain but that goes away. This is kind of different and it was really pain all over the body. He was wondering if these are signs of infection. He was asking if he can have this kind of reaction after this, after so long after the injection. Muscle pain was all over. He had chills that did not go away, and kind of trouble sleeping from them. Started last night when he went to sleep. It was just when he woke up that he was really sweaty when he woke up. Not really feeling well started last night. He felt fine now. He was going to get back to his normal routine. Once he gets off of the phone, he was going to go for a walk. States that last night couldn't sleep because his "body felt like a war zone". His main question was if can expect to get a reaction and side effects from the shot so many days later. He thought it would be 1 to 2 days normally after the second vaccination that these occur, but he has them after the first shot. The clinical outcome of the event pain all over body, muscle pain, slight chills, not really feeling well, joint pain, insomnia was unknown and recovered for injection site pain in Mar2021.  No follow-up attempts are possible. No further information is expected.
The day following the vaccine, I experienced a low grade fever (100.0), achiness down the arm of the injection, achiness in neck and other arm.  I had pain at the site of the injection, and couldn't lift my arm more than 30 degrees.  I also got a headache.  I had to lie down for most of the day following the vaccine.  All of those symptoms were gone by the next morning.  In the next 2 days, I had pain in the muscle that was vaccinated accompanied by muscle twitching.  It is now 6 days post-vaccination, and my muscle is very hard, like a knot, but not painful unless I rub it.  It hurts slightly to raise my arm, but doesn't affect my normal activity.
Pt. received Covid 19- Moderna vaccine on Left Deltoid at 10:13 AM. Pt was out in the recovery area for fifteen minutes. At 10:30 AM patient c/o dizziness. Pt was brought inside for further monitoring.  Vital signs were taken  at 10:40 HR 88, O2 98 % ,  BP 130/70.  Pt stated that she is feeling much better. Vital signs were retaken at 11:00 Am HR 89, O2 % 97 %, BP 135/ 70. Pt was sent home. Husband will be driving patient home. Pt.  to seek medical attention if she has any difficulty breathing.
she felt heavier; sleepiness; knees bothered her going up stairs; mild soreness at the injection site; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 19-Feb-2021 and was forwarded to Moderna on 20-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of DISCOMFORT (she felt heavier), SOMNOLENCE (sleepiness), ARTHRALGIA (knees bothered her going up stairs) and VACCINATION SITE PAIN (mild soreness at the injection site) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030L20A and 006M20A) for COVID-19 immunization.     No Medical History information was reported.   On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Feb-2021, the patient experienced DISCOMFORT (she felt heavier), SOMNOLENCE (sleepiness), ARTHRALGIA (knees bothered her going up stairs) and VACCINATION SITE PAIN (mild soreness at the injection site). On 18-Feb-2021, DISCOMFORT (she felt heavier), SOMNOLENCE (sleepiness), ARTHRALGIA (knees bothered her going up stairs) and VACCINATION SITE PAIN (mild soreness at the injection site) had resolved.            No treatment information was provided.
Similar to Anaphylaxis; Several severe reactions / Symptoms may be severe; This case was reported by a pharmacist via sales rep and described the occurrence of anaphylaxis in an unknown number of adult patients who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than a day after receiving Shingrix, the patient experienced anaphylaxis (serious criteria GSK medically significant) and adverse reaction. On an unknown date, the outcome of the anaphylaxis and adverse reaction were unknown.   It was unknown if the reporter considered the anaphylaxis and adverse reaction to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. It was reported that several severe reactions after receiving a 1st dose of Shingrix across multiple patients. The reporter described one reaction similar to anaphylaxis. The patient also stated that the day was shot after receiving a dose. The symptoms might be severe. The reporter consented to follow up. This case has been linked with the case US2020AMR102135 reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR102135:2nd dose
Fever (101.7) myalgias, chills, mild headache 24 hours after administration irritability/agitation immediately after vaccine
Johnson & Johnson shot this was not on the list. Hemiplegic reaction. Caused a stinging headache which then caused my entire right side to go numb and lose feeling from face to foot. Caused 6 hours of vomiting. Face and right arm are still numb to the touch. Lost 1 of the 3 nerve feelings on my right side.
severe headache; could not work the first 2 days; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 27Jan2021 15:45 (Lot number: EL9264) at the age of 62 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Allergy to nuts, mushrooms, oranges, grapefruit" (unspecified if ongoing); "dust allergy" (unspecified if ongoing); "Allergy to molds" (unspecified if ongoing); "kidney donor" (unspecified if ongoing). The patient took concomitant medications: unspecified estrogen patch. Past drug history included: Oxycodone, reaction(s): "drug allergy". The following information was reported: HEADACHE (non-serious) with onset 27Jan2021 16:00, outcome "not recovered", described as "severe headache"; IMPAIRED WORK ABILITY (non-serious) with onset 27Jan2021 16:00, outcome "not recovered", described as "could not work the first 2 days". The events "severe headache" and "could not work the first 2 days" were evaluated at the physician office visit. Therapeutic measures were taken as a result of headache.
3/12/21 developed dizziness, redness all over, 20 min after the injection the redness resolved.  Also c/o tinnitus and dizziness comes and goes.   Went to the ed x2 and saw pcp for dizziness.   Zofran was given for dizziness.  Going to see a neurologist on the 4/20/21
pt recv vax;sterile abscess formed on upper arm;seen MD;small lump p/ shot;noticed some crusting & peeling;soft palpable lump; no tx given, resolved in 3 wk;CHN advised to give deep im shot;par advised to call clinic if pt devel abscess
Information has been received from a consumer concerning her 12 year old daughter with seasonal allergy who in October 2008 was vaccinated with the first dose of GARDASIL, the second dose in December 2008, and the third dose on February 2009. Concomitant therapy included prednisone once daily and triamcinolone acetonide, 0.1 %, twice daily. In February 2009, the patient experienced severe skin allergies and she got hives and blisters all over her body. She was also experiencing severe headaches, dizziness and chest pains. The patient sought unspecified medical attention. There were no laboratory studies performed. At the time of report, the patient had not recovered. Additional information has been requested.
lot of pain in my joint especially my right knee I can't even touch it is so painful and really bad diarrhea I knew about the soreness of arm
Patient developed generalized, pruritic rash over back, chest, neck, scalp and the following day on lower legs.  Returned to Clinic.  Vital signs were stable.  Prescribed prn Vistaril and recommended Hydrocortisone 10% Cream.
On day of vaccination patient developed severe pruritis without obvious urticaria.  No SOB or respiratory complants.  On day 4 the arm was swollen and red with local reaction at 150 mm by 150 mm. Patient also had pain and itching at the injection site.  She was given IM kenalog and a tapering dose of prednisone by her PCP.  Also recommended elevation and steroid cream.  Off work for 1 day.  By day 6 the swelling was decreasing and patient had returned to work by day 7 with some residual swelling but much imporved.
pre-exposure series 11NOV94, 18NOV94, 9DEC94;titer drawn on 9JAN95=.25IU;pt will receive booster dose & redo titer;no immune problems
Warm, red, swollen and tender arm at injection site. Sore, achy muscles no joints. Headache and chills. Arm is still red, warm, tender and slightly swollen almost 36 hours later.
Immediately after the two shots, patient became pale, nauseous, and then vomited. Symptoms lasted 10 minutes.
30 yo healthy male received Pfizer BioNTech COVID vaccine #1 on 14 APR 21. He reported complete loss of taste and smell on day 3, which continued for 24 hours, and then slowly improved and resolved by day 5.  PCR testing for COVID infection was negative.
Patient in the spouse of a  employee. Employee contacted an RN requesting the RN reach out to her spouse regarding getting his second COVID  vaccination. The RN contacted the patient and per patient was told he had missed his UNCA second dose appointment and was very concerned due to his desire to be fully vaccinated. The RN discussed the intricacies of the  including the medication given at the clinic was MODERNA. Patient and spouse verbalized understanding. Patient was scheduled for a same day appointment. Patient arrived, filled out his paperwork, indicating he had previously received Pfizer. This was not observed by the Vaccination RN. Patient received the dose of MODERNA vaccination, and quickly after the vaccinating RN alerted the lead RN of the differences between the first vaccination the patient received and the second.  Provider Putnam was also alerted. Patient was observed for 15 minutes after the vaccine was given, per protocol, and was notified that he received the Moderna vaccination as his second dose. Patient was instructed to contact the facility or his PCP with any issues observed from the vaccine. Patient educated on expected side effects of Second Dose vaccination.
1. Fatigue, prolonged - started within several hours of administration and lasting in duration of 2-3 days. Alleviated with rest. 2. Muscle pain, administration site (R deltoid) - moderate pain started within several hours of administration but has reduced to mild discomfort after day 3.
Muscle aches all over-chills, fatigue, low grade fever 100.1-99.8.
2-3-inch rash where the vaccine was administered; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (2-3-inch rash where the vaccine was administered) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, the patient experienced VACCINATION SITE RASH (2-3-inch rash where the vaccine was administered). At the time of the report, VACCINATION SITE RASH (2-3-inch rash where the vaccine was administered) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment and concomitant medications were not provided by reporter.
No additional adverse events reported; improperly stored vaccines were potentially administered to unknown patients; This spontaneous report has been received from a licensed practical nurse, referring to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.    On 30-DEC-2021, the patient was vaccinated with improperly stored measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (recombinant Human albumin (rHA)) (M-M-R II) (lot # T033815 with expiration date: 05-OCT-2022, route, strength and dose were unknown) for prophylaxis (Product storage error). No additional adverse events reported.  Administered dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (recombinant Human albumin (rHA)) (M-M-R II) experienced the temperature excursion below 49.6 Fahrenheit degrees (F) for 35 hours 9 minutes. The previous temperature excursions were reported as 32.9F for 53 hours 16 minutes; 49. 1F for 5 hours 9 minutes; 56.3F for 14 hours 7 minutes.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2203USA003310: US-009507513-2203USA003311: US-009507513-2203USA003312: US-009507513-2203USA003313: US-009507513-2203USA003314: US-009507513-2203USA003315: US-009507513-2203USA003316: US-009507513-2203USA003317: US-009507513-2203USA003318: US-009507513-2203USA003319: US-009507513-2203USA003320: US-009507513-2203USA003321: US-009507513-2203USA003322: US-009507513-2203USA003323: US-009507513-2203USA003324: US-009507513-2203USA003325: US-009507513-2203USA003326: US-009507513-2203USA003327: US-009507513-2203USA003328: US-009507513-2203USA003329: US-009507513-2202USA003592: US-009507513-2203USA003331: US-009507513-2203USA003332: US-009507513-2203USA003333: US-009507513-2203USA003334: US-009507513-2203USA003335:
Patient reports that after receiving vaccine, later in the day the right side of her face started itching and she developed a fever blister.  By the end of the day the inside of her jaw and tongue felt swollen.  Vaccine site was slightly sore.  Patient called her MD on the 3 rd day but did not see anyone for medical treatment.  Took benadryl.  Had loss of appetite.
This case was reported by a pharmacist via call center representative and described the occurrence of fever in a 69-year-old female patient who received SHINGRIX (batch number 5NY3B, expiry date 13th July 2020) for prophylaxis. Previously administered products included ZOSTAVAX (received years before the date of reporting at her physician office). On 18th June 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 19th June 2018, 1 days after receiving SHINGRIX, the patient experienced fever. On 20th June 2018, the patient experienced injection site erythema and injection site swelling. On an unknown date, the outcome of the fever was recovered/resolved and the outcome of the injection site erythema and injection site swelling were recovering/resolving. It was unknown if the reporter considered the fever, injection site erythema and injection site swelling to be related to SHINGRIX. Additional details were reported as follows: The patient did not receive any concomitant medication. The patient received SHINGRIX on left arm. The patient came back to the pharmacy 2 days later with a large swollen red area of 8cm by 5cm on her injection arm at the site. The swelling and redness were improving the patient reported when the reporter spoke with the patient on the day of reporting. The batch number reported 3NY3B for SHINGRIX did not exist and was changed to 5NY3B as per sales database.
This spontaneous report was received from a nurse referring to two unspecified patients of unknown age and gender, both HIV positive. On 08-AUG-2017, the patients were vaccinated with PNEUMOVAX 23 lot # M042324, expiration date 10-JUN-2018, for prophylaxis. On 09-AUG-2017, both patients experienced fever (pyrexia), muscle aches (myalgia) and chills. The outcome of pyrexia, myalgia and chills was reported as not recovered/not resolved.
Patient reported chills, dizziness, weakness and needing help getting to and from the bathroom.
flu-like symptoms; body aches; chills; slight fever; listlessness; headaches; This is a spontaneous report from a contactable consumer(patient). A 42-year-old male patient received first dose of bnt162b2 (BNT162B2, Solution for injection, Lot: Not available) via unspecified route of administration on 02Feb2021 07:30 as single dose in left arm for Covid-19 immunisation in hospital. No other vaccine in four weeks was reported. Medical history reported was HIV+. Concomitant medications reported was bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate (BIKTARVY) and clarithromycin (CLARITIN), both as 1 a day. No Known allergies were reported. Patient was not tested positive covid prior vaccination nor covid tested post vaccination. Patient wanted to report that he had flu-like symptoms yesterday (04Feb21), he felt better today, but he did experience, body aches, chills, slight fever, and listlessness. He felt a little better today but truly felt like he was hit by a bus yesterday. He will continue to monitor symptoms as he felt much better today, but wanted to make aware of what he experienced. It started on 03Feb2021 with headaches. Patient did not receive any treatment in response to the events. Outcome of all the events was recovering.  Follow-up (19Apr2021): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.
Patient was given flu shot at 13:58 and instructed to wait 20 minutes in the clinic rest area in case of any reactions. Patient came back at 14:15 with complaints of itching on the face, around the nose and at vaccine site. Vital signs checked: temperature 98.9; pulse 63; respiratory rate 20; BP 109/53. Benadryl 50mg PO given. No respiratory distress. Patient told to wait 30 minutes and was discharged.
Pt feeling  dizzy, nauseated, and tingling sensation to left arm and bilateral feet. Pt also reported slight  SOB.  Vitals: HR63, O2 SAT 98%, NO tachypneic noted. Pt also noted to be pale and diaphoretic. Pt was advised to seat back and  given a bag to vomit in if needed. Patient encouraged  to stay  hydrated. After a few minute, patient  felt better . observed extra minutes  till patient felt better and  could drive
Shingles left side. T2 dematome. Pain on onset. Blisters appear 5 days after pain. As of 5/2/21 scabs almost gone. Pain in Demairo r continues.
22DEC93 mom reported that pt had a high pitched screaming for 4-5 hrs p/vax 20OCT93-t103;